Literature DB >> 10906646

Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients.

A K Gupta1, H C Jain, C W Lynde, P Macdonald, E A Cooper, R C Summerbell.   

Abstract

A prospective, multicenter study to determine the epidemiology of onychomycosis was performed in the offices of 3 dermatologists and 1 family physician in Ontario, Canada. In the sample of 15,000 patients, abnormal-appearing nails were observed in 2505 persons (16. 7%). There were 1199 patients (8%) with toenail or fingernail onychomycosis confirmed on mycologic examination, with 1137 patients (7.6%) who had only pedal onychomycosis, 40 patients with toenail and fingernail onychomycosis (0.27%), and 22 patients (0.15%) with only fingernail onychomycosis. The condition was more common in male patients (P <.0001) and older persons (P <.0001). The ratio of onychomycosis in toenails/fingernails was 19:1. When onychomycosis was present in toenails, the ratio of distal/lateral subungual onychomycosis (DLSO) to white superficial onychomycosis to proximal subungual onychomycosis was 360:59:1. The extent of DLSO in toenails was mild (< or =25% nail involvement), moderate (26%-74% disease), and severe (> or =75% nail involvement) in 27.6%, 39.9%, and 32.5% of patients, respectively. After adjusting for the age and sex distribution of the general population, the projected rate of onychomycosis in Canada is 6.5% (95% confidence interval [CI], 6. 1%-6.9%). The organisms causing toenail onychomycosis were 90.5% dermatophyte, 7.8% nondermatophyte molds, and 1.7% Candida spp. The corresponding organisms causing fingernail onychomycosis were 70.8%, 0%, and 29.2%, respectively. In a large sample of 15,000 patients, abnormal-appearing nails were present in 17% of the sample with mycologic evidence of toenail or fingernail onychomycosis in 8%. The projected prevalence of onychomycosis in Canada is 6.5% (95% CI, 6. 1%-6.9%).

Entities:  

Mesh:

Year:  2000        PMID: 10906646     DOI: 10.1067/mjd.2000.104794

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  61 in total

1.  Evaluation of the morphological effects of TDT 067 (terbinafine in Transfersome) and conventional terbinafine on dermatophyte hyphae in vitro and in vivo.

Authors:  M Ghannoum; N Isham; W Henry; H-A Kroon; S Yurdakul
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

2.  Increased Risk of Tinea Pedis and Onychomycosis Among Swimming Pool Employees in Netanya Area, Israel.

Authors:  Avner Shemer; Aditya K Gupta; Boaz Amichai; Sharon Baum; Aviv Barzilai; Renata Farhi; Yehonathan Kaplan; Melissa A MacLeod
Journal:  Mycopathologia       Date:  2016-07-19       Impact factor: 2.574

3.  In Vitro Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis.

Authors:  Natsuki Kubota-Ishida; Naomi Takei-Masuda; Kaori Kaneda; Yu Nagira; Tsubasa Chikada; Masahiro Nomoto; Yuji Tabata; Sho Takahata; Kazunori Maebashi; Xiaoying Hui; Howard I Maibach
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

4.  A study on clinico-mycological profile, aetiological agents and diagnosis of onychomycosis at a government medical college hospital in kashmir.

Authors:  Rubeena Lone; Deeba Bashir; Shabir Ahmad; Arshi Syed; Syed Khurshid
Journal:  J Clin Diagn Res       Date:  2013-09-10

Review 5.  Antibiofilm Treatment for Onychomycosis and Chronic Fungal Infections.

Authors:  Aditya K Gupta; Jessie Carviel; Neil H Shear
Journal:  Skin Appendage Disord       Date:  2017-10-11

Review 6.  Onychomycosis: modern diagnostic and treatment approaches.

Authors:  Georgi Tchernev; Plamen Kolev Penev; Pietro Nenoff; Liliya Georgieva Zisova; José Carlos Cardoso; Teodora Taneva; Gabriele Ginter-Hanselmayer; Julian Ananiev; Maya Gulubova; Reni Hristova; Desislava Nocheva; Claudio Guarneri; G Martino; Nobuo Kanazawa
Journal:  Wien Med Wochenschr       Date:  2012-09-30

7.  In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes.

Authors:  M Ghannoum; N Isham; L Long
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

8.  Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life.

Authors:  Antonella Tosti; Bom E Elewski
Journal:  J Clin Aesthet Dermatol       Date:  2014-11

9.  Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.

Authors:  William J Jo Siu; Yoshiyuki Tatsumi; Hisato Senda; Radhakrishnan Pillai; Takashi Nakamura; Daisuke Sone; Annette Fothergill
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

10.  Mechanism of Action of ME1111, a Novel Antifungal Agent for Topical Treatment of Onychomycosis.

Authors:  Sho Takahata; Natsuki Kubota; Naomi Takei-Masuda; Tsuyoshi Yamada; Mari Maeda; Mohamed Mahdi Alshahni; Shigeru Abe; Yuji Tabata; Kazunori Maebashi
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.